INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
06/08/2026
Voltar para busca
Dado oficial do USPTO
CUREVO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
06/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35
Data de depósito
29/09/2017
Data de registro
04/12/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/04/2025
Última transação
06/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Bothell, US
Examinador
BILLINGS, JOHN T
Localização atual
Historical data usage
Titulares e representantes
Titulares
Curevo Inc.
GREEN CROSS HOLDINGS CORPORATION
Representantes
Brendan J. Hughes Cooley LLP
Classificação técnica
Classes Nice
Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical agents affecting sensory organs; Thyroid and para-thyroid hormone preparations; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical agents affecting metabolism; Vaccines against flu; veterinary vaccines; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for regulating the immune system; Virucides; Vaccine preparations ; Adrenal hormone preparations; Pharmaceutical preparations and substances for use in gynecology; Pharmaceutical preparations for use in urology; Vitamin tablets; Pharmaceutical preparations for wounds; Pharmaceutical preparations for activating cellular function; Anti-inflammatory preparations; Pharmaceutical agents affecting digestive organs; Reagents for use in veterinary genetic testing; Pharmaceutical preparations for the treatment of cardiovascular disease; Ophthalmic preparations; Ophthalmologic preparations; Eye drops; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations and substances for the prevention of cancer; Biological preparations for the treatment of cancer; Pharmaceutical agents for epidermis; Sanitary sterilising preparations; Medicines for the treatment of gastrointestinal diseases; medicated mouth treatment preparations; Parasiticides for medical use; Diagnostic preparations for medical or veterinary purposes; Cleansing solutions for medical use; Cardiovascular agents for medical purposes; Reagents for medical use; Reagents for use in medical genetic testing; Hemostatics for medical purposes; Antibacterial substances for medical purposes; Diuretics; Insulin; Human vaccine preparations; General anesthetics; Pharmaceutical preparations for the treatment of auto-immune diseases; Multivitamin preparations; Pharmaceutical preparations acting on the central nervous system; Styptic pencils; Pharmaceutical preparations for treating asthma; Pharmaceutical solutions used in dialysis; Penicillin preparations; Antimicrobials for dermatologic use; Pharmaceutical preparations for treating skin disorders; Contraceptive preparations; Antihypertensives; Anti-diabetic pharmaceuticals; Antitoxins; Antivirals; Antiarrhythmic agents; Antibiotic preparations; Anti-cancer preparations; Anticoagulants; Tumor suppressing agents; Antifungal preparations; Anti-dermoinfectives; Antidotes; Antipyretic analgesics; Vasoconstrictors; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Mixed antibiotic preparations; Mixed hormone preparations; Chemotherapeutics; Pharmaceutical preparations for use in discouraging the smoking habit
Classe 35
Retail and wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; advertising services relating to pharmaceutical products; advertising relating to pharmaceutical products and in-vivo imaging products
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
20/07/2026
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
16/07/2026
INPC
INVALIDATION PROCESSED
16/07/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
26/12/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
22/12/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
26/04/2025
71AG
REGISTERED-SEC.71 ACCEPTED
26/04/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/04/2025
ES71
TEAS SECTION 71 RECEIVED
05/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/06/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/06/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/06/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/06/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/12/2023
CHLD
CHANGE OF OWNER RECEIVED FROM IB
22/09/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/04/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/03/2019
FIMP
FINAL DISPOSITION PROCESSED
15/03/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/03/2019
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/12/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
04/12/2018
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
30/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/09/2018
PUBO
PUBLISHED FOR OPPOSITION
18/09/2018
GPNX
NOTIFICATION PROCESSED BY IB
15/09/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/08/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/07/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/07/2018
ALIE
ASSIGNED TO LIE
20/07/2018
ALIE
ASSIGNED TO LIE
18/07/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/07/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/07/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/07/2018
RFNT
REFUSAL PROCESSED BY IB
10/02/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/01/2018
RFRR
REFUSAL PROCESSED BY MPU
20/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/01/2018
CNRT
NON-FINAL ACTION WRITTEN
09/01/2018
DOCK
ASSIGNED TO EXAMINER
08/01/2018
MAFR
APPLICATION FILING RECEIPT MAILED
09/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/11/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CUREVO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.